Karyopharm Therapeutics Balance Sheet - Annual (NASDAQ:KPTI)

Add to My Stocks
$18.57 $0.57 (3.17%) KPTI stock closing price Sep 18, 2018 (Closing)

The financial analysis of a company involves interpreting the income statement, balance sheet and cash flow statements of the company to draw insights like we've done in our Karyopharm Therapeutics stock analysis. All three financial statements should be used to measure the financial performance of the company, and should form a part of the Karyopharm Therapeutics stock analysis. Good annual results indicate a company's strong financial performance. Its important to check all financial statements including the balance sheet. Karyopharm Therapeutics balance sheet indicates an asset turnover ratio of 0.4 and debt to equity ratio of 0. Also check Karyopharm Therapeutics revenue and Karyopharm Therapeutics operating cash flow for the same period.

View latest 10 year balance sheet data to check Karyopharm Therapeutics financial performance.
show more
View Previous Years
View Next Years
Fiscal year is Jan - Dec2017201620152014201320122011
Marketable Securities77.47M79.88M117.27M55.11M---
Raw Materials-------
Work In Progress-------
Finished Goods-------
Notes Receivable-------
Other Current Assets1.75M2.08M1.96M2.02M1.98M--
Total Current Assets
Property Plant & Equipment4.74M4.68M4.61M3.24M---
Accumulated Depreciation2.55M1.84M1.12M----
Net Property Plant & Equipment
Investment & Advances29.39M45.43M33.87M8.65M---
Other Non-Current Assets-------
Deferred Charges-------
Deposits & Other Assets---1.17M---
Total Assets
Notes Payable-------
Accounts Payable5.66M4.75M3.8M6.28M1.74M1.07M1.14M
Current Portion Long-Term Debt-------
Current Portion Capital Leases-------
Accrued Expenses21.44M11.36M11.02M5.82M1.16M--
Income Taxes Payable-------
Other Current Liabilities22.35M------
Total Current Liabilities
Deferred Taxes/Income1.36M1.66M1.94M1.24M---
Convertible Debt-------
Long-Term Debt-------
Non-Current Capital Leases-------
Other Long-Term Liabilities------10.77M
Total Liabilities
Minority Interest------6.98M
Preferred Stock-----27.25M-
Common Stock Net-------
Capital Surplus625.01M528.61M455.17M345.16M217.5M--
Retained Earnings-495.34M-366.1M-256.52M-138.34M-62.56M-28.62M-12.73M
Treasury Stock-------
Other Liabilities-0.21M-0.27M-0.28M-0.02M---
Shareholders Equity129.46M162.24M198.36M206.79M154.93M-0.61M-12.65M
Total Liabilities & Shareholders Equity180.29M180.38M215.44M220.33M158.22M1.31M7.22M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Looking at Karyopharm Therapeutics historical stock prices and the current Karyopharm Therapeutics stock price can tell you how the stock price has moved, whereas the Karyopharm Therapeutics PE ratio chart shows if its shares are overpriced in comparison to peers. The important things to look for in a balance sheet are:

  • Assets: Anything that the Karyopharm Therapeutics company owns and is a part of its books. Assets can be of three types: fixed, current and other assets which includes intangibles, advances. Internet companies typically don't have a lot of assets as there is not much investment in say machinery, equipment etc. Karyopharm Therapeutics had total assets of $180.29M.
  • Liabilities: This item on the balance sheet implies the firm's, in this case Karyopharm Therapeutics's, legal obligations including loans, accounts payable, deferred revenue, accrued expenses and mortgages. The total liabilities for KPTI stock stand at $50.83M.

Karyopharm Therapeutics Balance Sheet - Key Ratios

Current ratio
Debt to equity ratio
Asset turnover ratio
Receivables turnover
Price to book ratio